Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study
{{output}}
Circulating tumor DNA (ctDNA) derived from blood samples can serve as a minimally invasive, real-time indicator of tumor burden and treatment response in metastatic colorectal cancer. This study evaluated the association between baseline ctDNA levels and chang... ...
